Skip to main content
    C

    Candel Therapeutics Inc (CADL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.40
    -0.41 (-7.06%)

    Market Cap: $486.37M

    Last updated: Nov 17, 2026 at 4:35 PM ET

    Candel Therapeutics Inc (CADL) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Candel Therapeutics (CADL) has a market cap of $486.37M and an enterprise value of $331.45M. Its share count is up 40.97% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 31.85% below the market cap, as cash exceeds debt.

    Market Cap$486.37M
    Enterprise Value$331.45M
    Latest price (Nov 17, 2026)$5.40

    Key Dates

    The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 10, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 4.39% in the quarter ended Sep 30, 2026 and grew 55.48% a year over 2 years.

    Shares Outstanding77.39M
    Shares Change (YoY)+40.97%
    Shares Change (QoQ)+4.39%
    Share Count Growth (2Y CAGR)+55.48%

    Price Statistics

    The stock is up 16.38% over 52 weeks and trades 42.98% below its 50-day average.

    Beta (1Y)2.19
    52-Week Change+16.38%
    1-Month Change-34.23%
    3-Month Change-60.00%
    6-Month Change-29.50%
    5-Year Change-25.82%
    Total Return (1Y)+16.38%
    Total Return (5Y CAGR)-12.79%
    Return vs SPY (1Y)+5.32%
    Max Drawdown (1Y)-60.73%
    Max Drawdown (3Y)-72.86%
    Sharpe Ratio (1Y)0.20
    Correlation with SPY (1Y)0.38
    50-Day Average$9.47
    200-Day Average$8.40
    52-Week Range$4.35 to $14.00
    RSI (14 Days)27.5
    Average Volume (20 Days)1.55M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 7.57x current liabilities, and total debt is 0.37x shareholder equity.

    Current Ratio7.57x
    Quick Ratio7.57x
    Debt / Equity0.37x
    Interest Coverage-16.09x

    Returns and Efficiency

    Return on invested capital is -43.46% over the last 12 months, against a 5-year average of -48.56%.

    Return on Equity (ROE)-75.34%
    Return on Assets (ROA)-46.96%
    Return on Invested Capital (ROIC)-43.46%
    Return on Capital Employed (ROCE)-53.83%
    ROA (5Y Average)-47.78%
    ROIC (5Y Average)-48.56%

    Scores

    CADL has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit-$163.00K
    Operating Income-$81.76M
    Pretax Income-$99.14M
    Net Income-$99.14M
    EBIT-$98.90M
    Reported EPS (TTM)-$1.06

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 62.33% of the $211.11M in total assets.

    Cash and Equivalents$203.12M
    Total Debt$48.20M
    Net Cash$154.92M
    Net Cash Per Share$2.00
    Working Capital$179.97M
    Shareholder Equity$131.59M
    Book Value Per Share$1.70
    Total Assets$211.11M
    Total Liabilities$79.52M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $1.29M of capital spending, operating cash flow left -$70.20M of free cash flow.

    Operating Cash Flow-$68.91M
    Capital Expenditures$1.29M
    Free Cash Flow-$70.20M
    FCF Per Share-$0.92
    Depreciation and Amortization$654.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)+46.65%
    Tangible Book Per Share Growth (2Y CAGR)+46.65%

    Revenue and profit by year

    Dividends and Yields

    CADL does not pay a dividend. Its free cash flow yield is -16.80%.

    FCF Yield-16.80%
    Buyback Yield-33.98%
    Shareholder Yield-33.98%

    Peer Position

    Against 4 similar companies, CADL has the 3rd highest ROIC.

    ROIC-43.46% vs -57.13% median
    Revenue Growth (Trailing 4 Quarters, YoY)-100.00% vs -100.00% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About CADL

    What is CADL's market cap?

    Candel Therapeutics has a market cap of $486.37M. Its enterprise value, which adds debt and subtracts cash, is $331.45M.

    How many shares of CADL are outstanding?

    Candel Therapeutics has 77.39M shares outstanding. The count is up 40.97% from a year earlier.

    Does CADL pay a dividend?

    No. Candel Therapeutics does not pay a dividend.

    How much debt does CADL have?

    Candel Therapeutics has $48.20M of total debt and $203.12M of cash and equivalents, a net cash position of $154.92M.